Dupilumab in Chronic Rhinosinusitis Without Nasal Polyps: Randomized Phase 2 Trial (ORION)

Authors

• Stella E. Lee, Harvard Medical School
• Anju T. Peters, Northwestern University
• Philippe Gevaert, Ghent University
• Joseph K. Han, Macon & Joan Brock Virginia Health Sciences at Old Dominion UniversityFollow
• Claus Bachert, University Hospital of Münster
• Francisco Moreira da Silva, Hospital Senhora da Oliveira
• Andrés Rosenblüt, Hospital Dr Sotero del Rio
• Chih-Chi Hu, Sanofi, Morristown
• Jennifer Maloney, Regeneron Pharmaceuticals Inc.
• Paolo Caferra, University of Pisa
• Adrianna Michalak, Sanofi, Toronto
• Andrew P. Fontenot, Regeneron Pharmaceuticals Inc.
• Lacey B. Robinson, Sanofi, Cambridge
• Neelam A. Phadke, Sanofi, Cambridge

Document Type

Article

Publication Date

2026

DOI

10.4193/Rhin25.660

Publication Title

Rhinology

Volume

Advance online publication

Pages

24 pp.

Abstract

BACKGROUND: Chronic rhinosinusitis (CRS) is often driven by type 2 inflammation and is characterized by nasal obstruction/ discharge, facial pain/pressure, and/or reduced smell, either with or without nasal polyps (CRSwNP or CRSsNP).

OBJECTIVE: To test whether dupilumab improves radiographic features in CRSsNP. Methods: ORION (NCT04678856), a phase 2, randomized, multicenter, double blind, placebo-controlled study, assessed dupilumab efficacy and safety in adults with uncontrolled CRSsNP. Patients were randomized 1:1 to dupilumab or placebo for 24 to 52 weeks. Endpoints included changes from baseline at week 24 in Lund–Mackay computed tomography (LMK-CT) score (dupilumab only [primary] and vs placebo [secondary]), sinus Total Symptom Score (sTSS), University of Pennsylvania Smell Identification Test (UPSIT) score, and 22-item Sino-Nasal Outcome Test(SNOT-22) score. Primary analysis was conducted in the intention-to-treat population with screening blood eosinophil count (sBEC) ≥300 cells/μL. Safety data were evaluated in all patients.

RESULTS: Seventy-one patients were randomized (dupilumab, n = 38; placebo, n = 33). In the dupilumab group with sBEC ≥300 cells/μL (n = 16), mean (95% CI) week 24 change from baseline in LMK-CT was -6.63 (-8.71 to -4.54); week 24 mean differences vs placebo (95% CI) for LMK-CT, sTSS, UPSIT, and SNOT-22 were -5.95 (-8.38 to -3.51), -1.43 ( 3.28 to 0.41), 5.91 (-1.56 to 13.38), and -14.71 (-34.35 to 4.94). Treatment-emergent adverse events were balanced between treatment groups.

CONCLUSION: Dupilumab was associated with improvement in LMK-CT score and a trend toward improvement in sinonasal symptoms at week 24 in adults with severe, uncontrolled CRSsNP with sBEC ≥300 cells/μL.

Rights

"Authors can post the final, published PDF of their article on a website, institutional repository, or other free public server."

Original Publication Citation

Lee, S. E., Peters, A. T., Gevaert, P., Han, J. K., Bachert, C., Moreira da Silva, F., Rosenblüt, A., Hu, C. C., Maloney, J., Caferra, P., Michalak, A., Fontenot, A. P., Robinson, L. B., & Phadke, N. A. (2026). Dupilumab in chronic rhinosinusitis without nasal polyps: Randomized phase 2 trial (ORION). Rhinology. Advance online publication. https://doi.org/10.4193/Rhin25.660

Repository Citation

Lee, S. E., Peters, A. T., Gevaert, P., Han, J. K., Bachert, C., Moreira da Silva, F., Rosenblüt, A., Hu, C. C., Maloney, J., Caferra, P., Michalak, A., Fontenot, A. P., Robinson, L. B., & Phadke, N. A. (2026). Dupilumab in chronic rhinosinusitis without nasal polyps: Randomized phase 2 trial (ORION). Rhinology. Advance online publication. https://doi.org/10.4193/Rhin25.660